Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients with Adv Solid Tumors

Trial Identifier:	MSC-1-101
Sponsor:	AstraZeneca
NCTID::	NCT03490669
Start Date:	May 2018
Primary Completion Date:	September 2019
Study Completion Date:	September 2019
Condition:	Cancer - Other; Lung Cancer; Ovarian Cancer; Pancreatic Cancer

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Country	Location
Canada, Ontario	Toronto, Ontario, Canada, M5G 1Z5
Spain	Barcelona, Spain, 08035
United States, Arizona	Scottsdale, Arizona, United States, 85258
United States, Michigan	Grand Rapids, Michigan, United States, 49546
United States, New Jersey	Middletown, New Jersey, United States, 07748
United States, New York	New York, United States, 10065
United States, New York	West Harrison, New York, United States, 10604